Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Sandra M. Swain(Georgetown University), Richard A. Gams(Breast Center), Michael York(Breast Center), Stuart P. Weisberg(Columbia University), Kelly Pendergrass(Breast Center), James L. Speyer(Breast Center), E Vélez-García(Breast Center), Scott Wadler(Breast Center), Sarah E. Jones(Breast Center), Michael S. Ewer(Washington Hospital), Salitha Reddy(Breast Center), A Mittelman(Breast Center), Fredrick S. Whaley(Breast Center), J. R. Bianchine(Breast Center), Charles L. Vogel(Cancer Research Institute), Anjali Desai(Breast Center), Darcy Spicer(Breast Center), Mirjam C. Gerber(Breast Center)
Cited by 652
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
|Journal of Clinical Investigation|2005|1.5k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k
Targeting HER2-positive breast cancer: advances and future directions
|Nature Reviews Drug Discovery|2022|1k